When many people first heard the term “designer babies,” it sounded like science fiction. Something less biological and more Hollywood. However, the discussion is no longer theoretical when one walks through contemporary genetics labs, which are filled with glowing computer screens, sequencing machines, and microscopes.
It is based on a technology called CRISPR-Cas9, which enables scientists to precisely cut and rewrite DNA. It is frequently referred to by researchers as a type of molecular word processor that can fix genetic errors in the code of life.
That ability has the potential to eradicate thousands of hereditary diseases.
However, changing the DNA of human embryos is a far more contentious use for the same technology.
The debate starts with that distinction between curing illness and redesigning future generations.
| Category | Details |
|---|---|
| Technology | CRISPR-Cas9 |
| Key Scientist | Jennifer Doudna |
| Major Controversy | 2018 birth of gene-edited twins by He Jiankui |
| Research Focus | Editing DNA to cure genetic diseases |
| Ethical Concern | Germline editing that permanently alters future generations |
| Regulatory Bodies | National Institutes of Health and international bioethics councils |
| Reference Website | https://www.genome.gov |
When biochemist Jennifer Doudna and her colleagues showed that bacteria have a natural mechanism for cutting viral DNA more than ten years ago, the scientific tale began in silence. Laboratories all over the world started experimenting with the mechanism almost immediately after scientists realized it could be modified for gene editing.
The rate of discovery was astounding in just a few years. In clinical trials, the genes causing uncommon blood disorders were altered. In animals, researchers fixed mutations that had previously resulted in blindness. Some experiments even suggested that sickle cell disease and other hereditary disorders might eventually go away.
There was genuine excitement.
However, the anxiety was also present.
Adult gene editing, which scientists refer to as somatic editing, only has an impact on the individual patient. Changing embryos is not the same. At that point, changes are incorporated into the human germline, which allows them to be passed down from one generation to the next.
Any error would be irreversible.
When Chinese researcher He Jiankui revealed that he had produced the first gene-edited babies in history in 2018, that reality suddenly became widely known. He modified their embryos in an effort to make the twin girls, publicly known as Lulu and Nana, resistant to HIV.
The scientific community was taken aback by the announcement.
Researchers reportedly checked their phones for confirmation while whispering in the hallways of conferences that year. Germline editing was thought to be years away from being used in clinical settings. All of a sudden, it had already occurred.
The response was quick and remarkably cohesive.
Prominent scientists denounced the experiment as careless, claiming that the technology was just not ready. Even gene editing enthusiasts were concerned that early experiments might undermine public confidence in the field as a whole.
He was eventually imprisoned by Chinese authorities for breaking medical regulations.
However, the fundamental problem never went away.
CRISPR is still an incredibly potent tool, and its potential advantages are hard to overlook. Single defective genes are the cause of genetic diseases such as Tay-Sachs, Huntington’s disease, and cystic fibrosis. Theoretically, many families could avoid suffering if those genes were edited before birth.
It’s simple to see why the concept has such emotional appeal when you’re standing in a waiting area of a fertility clinic and listening to hopeful parents’ quiet conversations.
However, the door to genetic editing rarely remains closed once it opens.
Nowadays, disease prevention is the main topic of discussion when it comes to technology. Tomorrow, the discussion may broaden to include characteristics that are not strictly medical, such as intelligence, athletic prowess, height, or appearance.
This is referred to by scientists as “enhancement.”
And many ethicists are concerned about that possibility.
Some are concerned that gene editing may eventually worsen social inequality by establishing what some refer to as a genetic class system. Rich families may be able to purchase genetic advancements that others cannot, providing their offspring with biological advantages from birth.
It sounds like a radical idea.
However, history provides unsettling reminders. Through selective breeding and genetic control, early twentieth-century eugenics movements—now widely denounced—also claimed to improve society.
There’s a feeling that scientists are keenly aware of that past as the CRISPR controversy develops.
There is another issue that is equally important but more technical.
Despite its reputation for accuracy, CRISPR can sometimes cut DNA in unexpected places; this is referred to as “off-target editing.” These unintentional mutations may not manifest right away. In certain instances, they may raise the chance of developing cancer or cause new genetic issues decades later.
Furthermore, the effects may go well beyond the original child because germline edits are passed down through generations.
That uncertainty is acknowledged even by proponents of gene editing.
For this reason, many nations have set stringent restrictions. Heritable genome editing clinical trials are not supported by the National Institutes of Health in the United States. The UK forbids using embryos for reproduction but permits restricted research on them.
The scientific community is still cautious on a global scale.
Many researchers advise continuing to study the technology. However, do not yet use it to produce genetically altered offspring.
Nevertheless, there is increasing pressure to proceed.
Startups in biotechnology see huge commercial potential. Some futurists envision a society in which parents regularly check embryos for genetic advantages. In an effort to improve the accuracy and predictability of the process, venture capitalists covertly fund studies investigating the next generation of gene-editing tools.
It appears that investors seldom exercise scientific caution with patience.
And society as a whole might eventually have to make tough decisions.
Would parents feel compelled to use gene editing if it could stop terrible diseases? Would children be at a disadvantage if improvements were made possible? The distinction between improvement and therapy may become more hazy than anticipated.
It’s difficult to ignore the mix of optimism and anxiety surrounding the technology as this debate develops.
One amazing feature of CRISPR is its capacity to alter the biological instructions that determine human existence.
For decades to come, scientists, decision-makers, and future parents may argue over whether or not humanity is smart enough to use that power responsibly.
